CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company, is focused on developing high-value human therapeutics. Their drug development pipeline includes six programs in clinical development. The Company owns and operates a research and development facility in San Diego, California, and holds a 45% equity interest in RXi Pharmaceuticals (NasdaqCM: RXII ). For further information, visit the Company’s web site at www.cytrx.com.
- 17 years ago
QualityStocks
CytRx Corporation (NASDAQ: CYTR)
Tags Rodman & Renshaw
Related Post
-
MoneyShow Presents Real Estate Plays for Profit and Income Expo
MoneyShow has empowered individual investors and traders with state-of-the-art tools, education, and access to specific…
-
New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Eyes Bolivia’s Untapped Silver Potential Amid Global Supply Gaps
Bolivia, despite its rich mining history, remains one of the most underexplored silver jurisdictions due…
-
Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
Ricin toxin is a potent biothreat, so lethal that even a dose the size of…